Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients


  • Funding: None.

  • Conflict of interest: Dr Kerdel has received grants, participated in advisory boards and is speaker for: Abbott, Amgen, Wyeth, Astellas, Centocor, Genentech, Stiefel, Eisai, Merck and Novartis. Drs Vitiello, Tosti, Abuchar and Zaiac do not have any conflict of interest to disclose.

Francisco A. Kerdel, BSc, MBBS
Florida Academic Dermatology Center Director of Dermatology Inpatient Service
University of Miami Hospital
1400 N.W. 12th Ave, Ste. 4
Miami, FL 33136

No abstract is available for this article.